NVO - Hims & Hers defended at BofA as Lilly fights compounded GLP-1s
2024-06-21 09:44:16 ET
More on Hims & Hers Health
- Hims & Hers: The Undervalued Gem Poised For Growth
- Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead
- Hims & Hers: Ready For Takeoff
- Hims & Hers cut to Neutral at Citi on recent rally
- Hims & Hers surges on cheap compounded versions of Novo Nordisk's semaglutide